ClinicalTrials.gg
Active, not recruitingNCT06321757PARISUpdated Jul 6, 2026

PREVAIL Paclitaxel-coated Balloon in Small Coronary Disease and High-bleeding Risk Patients

An observational study in Coronary Artery Disease, sponsored by Fundación EPIC. Active, not recruiting at 19 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by Fundación EPIC · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
501
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Coronary Artery Disease by Fundación EPIC — 13 open to participants now, 20 under way, none of them phase 3. Coronary Artery Disease · Fundación EPIC.

Enrollment
6th of 20
501 · median 375
Started
2024
with 5 others
Observational
20 of 33
5 open now
Primary completion
2026-12
later than 5 of 19 live
Registered
23rd of 33
by date

Among the 33 studies in Coronary Artery Disease by Fundación EPIC, this one is the 6th largest by enrollment of the 20 observational ones that give a count, is one of 6 that started in 2024, is one of 20 observational ones, reaches primary completion later than 5 of the 19 other live ones, and was the 23rd registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

13 of the 33 studies in Coronary Artery Disease by Fundación EPIC are open now, in 7 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Coronary Artery Disease by Fundación EPIC, or all of them as a file.
02

Study summary

Post-market, prospective, observational, multicenter, non-intervention study, to demonstrate the effectiveness of drug-coated ballon (DCB)therapy in real-world patients with small native vessel coronary artery disease, and to demonstrate the safety of short dual antiplatelet therapy (7 days) in high-bleeding risk patients with native small vessel coronary artery disease treated with DCB therapy. A percutaneous coronary intervention (PCI) with DCB will be performed in patients with native vessel coronary artery disease based on the criterion of the treating physician.

Read the detailed description

Post-market, prospective, multicenter, non-intervention study, to demonstrate the effectiveness of drug-coated ballon therapy in real-world patients with small native vessel coronary artery disease, and to demonstrate the safety of short dual antiplatelet therapy (7 days) in high-bleeding risk patients with native small vessel coronary artery disease treated with DCB therapy. A PCI with DCB will be performed in patients with native vessel coronary artery disease based on the criterion of the treating physician. The angiographic study will be analyzed in a core lab (icicorelab) blinded to the procedural outcomes and the patients' follow-up.

As per clinical practice, 1-year clinical follow-up of all the patients will be conducted with a first assessment at 30 days, a second assessment at 6 months, and one final assessment at 12 months.

Should the patient have an elevated bleeding risk -defined as concomitant therapy with oral anticoagulation or a PRECISE-DAPT score ≥ 25- patients will be included in a high-bleeding risk substudy. The antiplatelet therapy regime will be administered according to the local investigator and the treating medical team.

03

Conditions studied

  • Coronary Artery Disease

Keywords

  • drug-coated balloon
  • paclitaxel
  • small native vessel coronary artery disease
  • coronary stenoses
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

drug-coated ballon therapy in real-world patients with small native vessel coronary artery disease

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients with:

  • PCI with DCB on native arteries with diameters \< 3 mm.
  • Indication for PCI in acute coronary syndrome or chronic coronary syndrome or silent angina with an indication for PCI.

syndrome or silent angina with an indication for PCI.

  • If previous lesion preparation was required after which angiographic residual lesion should not exist with diameter stenosis > 30% or flow-limiting coronary dissections.
  • All antithrombotic therapies administered prior to the procedure are accepted. Still, they can be changed after the procedure.
  • Capacity to understand and sign the written .
  • If the patient has a high-bleeding risk defined by 1) PRECISE-DAPT SCORE ≥ 25 or 2) an indication for concomitant oral anticoagulation he can be included in the high- bleeding risk substudy as long as he does not meet the specific exclusion criteria.

Exclusion criteria

Exclusion Criteria:

Patients with:

  • Concomitant lesions on vessels > 3 mm in diameter in the same coronary territory.
  • PCI on in-stent restenoses.
  • PCI on culprit lesions of acute coronary syndrome with ST segment elevation.
  • Patients with an indication for PCI on additional non-culprit lesions of acute coronary syndrome with ST segment elevation may be included in the study, if only non-culprit lesions are considered for the study.
  • \<12 months
  • Pregnancy.
  • Participation in clinicaltrials.
  • Inability to give the written .
  • Specific exclusion criteria for the high-bleeding risk patient subgroup:
  • Past medical history of stent thrombosis.
  • Indication for dual antiplatelet therapy for a different reason.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
501 participants (actual)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • Patients with small native vessel coronary artery disease

    \- Patients with small native vessel coronary artery disease y/or patients with High Bleeding Risk

    Device: Percutaneous Coronary Intervention with DCB and DAPT

Interventions

  • DevicePercutaneous Coronary Intervention with DCB and DAPT

    * Patients with PCI (DCB) + standard DAPT standard dual antiplatelet therapy (DAPT) * Patients with PCI (DCB) + short DAPT

06

What researchers measure

Primary outcomes

  1. Effectiveness of DCB therapy

    Incidence of MACE, which is a composite endpoint including cardiac mortality, myocardial infarction, and new revascularization of the target lesion

    Time frame: 1 year

Secondary outcomes

  1. Cardiac death

    Incidence of Cardiac death

    Time frame: 1 year

  2. All-cause mortality

    Incidence of All-cause mortality

    Time frame: 1 year

  3. Target vessel myocardial infarction

    Incidence of Target vessel myocardial infarction

    Time frame: 1 year

  4. New target lesion revascularization (TLR)

    Incidence of New target lesion revascularization (TLR)

    Time frame: 1 year

  5. Target vessel failure (TVF)

    Incidence of Target vessel failure (TVF)

    Time frame: 1 year

  6. Major bleeding

    Bleeding defined as BARC (Bleeding Academic Research Consortium) criteria 2,3 or 5

    Time frame: 1 year

  7. Minor bleeding

    Anemia, defined as Hb\<12g/dL for women and \<13g/dL for men

    Time frame: 1 year

  8. 1-year MACE indicende (cardiac mortality, myocardial infarction, and new revascularization of the target lesion) in high-bleeding risk patients treated with a short dual antiplatelet treatment (7 days)

    safety analysis of short DAP (dual antiplatelet therapy) in terms of thrombotic risk after PCI

    Time frame: 1 year

07

Study locations

19 sites
08

References and documents

Publications

  • Gruntzig A. Transluminal dilatation of coronary-artery stenosis. Lancet. 1978 Feb 4;1(8058):263. doi: 10.1016/s0140-6736(78)90500-7. No abstract available. PubMed 74678 ↗
  • Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med. 1987 Mar 19;316(12):701-6. doi: 10.1056/NEJM198703193161201. PubMed 2950322 ↗
  • Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R; RAVEL Study Group. Randomized Study with the Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in the Treatment of Patients with de Novo Native Coronary Artery Lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002 Jun 6;346(23):1773-80. doi: 10.1056/NEJMoa012843. PubMed 12050336 ↗
  • Kirtane AJ, Gupta A, Iyengar S, Moses JW, Leon MB, Applegate R, Brodie B, Hannan E, Harjai K, Jensen LO, Park SJ, Perry R, Racz M, Saia F, Tu JV, Waksman R, Lansky AJ, Mehran R, Stone GW. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation. 2009 Jun 30;119(25):3198-206. doi: 10.1161/CIRCULATIONAHA.108.826479. Epub 2009 Jun 15. PubMed 19528338 ↗
  • Kleber FX, Schulz A, Waliszewski M, Hauschild T, Bohm M, Dietz U, Cremers B, Scheller B, Clever YP. Local paclitaxel induces late lumen enlargement in coronary arteries after balloon angioplasty. Clin Res Cardiol. 2015 Mar;104(3):217-25. doi: 10.1007/s00392-014-0775-2. Epub 2014 Oct 28. PubMed 25349065 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Dec 2026, 34 months after the start.

Of 637 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's planned 34 months is below that.

Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2024
First posted
Mar 20, 2024
StartActual
Feb 26, 2024
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06321757
Lead sponsor
Fundación EPIC
Responsible party
Sponsor
First posted
Mar 20, 2024
Start date
Feb 26, 2024
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Jul 6, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion